Identification

Name
Cinchocaine
Accession Number
DB00527  (APRD00915)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)

Structure
Thumb
Synonyms
  • 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide
  • 2-Butoxy-N-(alpha-diethylaminoethyl)cinchoninamide
  • 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide
  • 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide
  • 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide
  • 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide
  • 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide
  • alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine
  • alpha-Butyloxycinchoninic acid diethylethylenediamide
  • CINCHOCAINE
  • Cinchocainum
  • Cincocainio
  • Dibucaine
  • Dibucaine base
  • N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide
Product Ingredients
IngredientUNIICASInChI Key
Cinchocaine hydrochlorideZ97702A5DG61-12-1IVHBBMHQKZBJEU-UHFFFAOYSA-N
Dibucaine hydrochlorideNot AvailableNot AvailableNot applicable
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CVS Hemorrhoidal Topical AnalgesicOintment10 mg/gTopicalCvs Health2014-01-17Not applicableUs
DibucaineOintment1 g/100gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1968-01-01Not applicableUs
DibucaineOintment.28 g/28gTopicalGeritrex Llc2014-01-06Not applicableUs
DibucaineCream10 mg/gTopicalCvs Health2010-07-16Not applicableUs
DibucaineOintment1 g/100gTopicalPerrigo New York Inc.2011-06-20Not applicableUs
NupercainalOintment1 g/100gTopicalDr Reddy's Laboratories2013-07-01Not applicableUs
Nupercainal Anesthetic Ointment 1%Ointment1 %Rectal; TopicalGlaxosmithkline Inc1944-12-31Not applicableCanada
International/Other Brands
Cincain / Nupercaine / Sovcaine
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Nupercainal Antiseptic CreamCinchocaine (0.5 %) + Domiphen bromide (0.05 %)CreamTopicalGlaxosmithkline Inc1967-12-31Not applicableCanada
Proctol OintmentDibucaine hydrochloride (0.5 %) + Esculin (1 %) + Framycetin sulfate (1 %) + Hydrocortisone (0.5 %)OintmentRectalOdan Laboratories Ltd2003-08-06Not applicableCanada
Proctol SuppositoriesDibucaine hydrochloride (0.5 %) + Esculin (1 %) + Framycetin sulfate (1 %) + Hydrocortisone (0.5 %)SuppositoryRectalOdan Laboratories Ltd2004-03-15Not applicableCanada
Proctosedyl OintmentDibucaine hydrochloride (5 mg) + Esculin (10 mg) + Framycetin sulfate (10 mg) + Hydrocortisone (5 mg)OintmentRectalHoechst Roussel Canada Inc.1971-12-312006-07-28Canada
Proctosedyl OintmentDibucaine hydrochloride (5 mg) + Esculin (10 mg) + Framycetin sulfate (10 mg) + Hydrocortisone (5 mg)OintmentRectalRoussel Canada Inc.1959-12-311997-08-05Canada
Proctosedyl OintmentDibucaine hydrochloride (0.5 %) + Esculin (1 %) + Framycetin sulfate (1 %) + Hydrocortisone (0.5 %)OintmentRectalAptalis Pharma Canada Ulc2003-04-01Not applicableCanada
Proctosedyl SupDibucaine hydrochloride (5 mg) + Esculin (10 mg) + Framycetin sulfate (10 mg) + Hydrocortisone (5 mg)SuppositoryRectalRoussel Canada Inc.1959-12-311996-09-09Canada
Proctosedyl SuppositoriesDibucaine hydrochloride (0.5 %) + Esculin (1 %) + Framycetin sulfate (1 %) + Hydrocortisone (0.5 %)SuppositoryRectalAptalis Pharma Canada Ulc1997-01-23Not applicableCanada
Proctosedyl SuppositoriesDibucaine hydrochloride (5 mg) + Esculin (10 mg) + Framycetin sulfate (10 mg) + Hydrocortisone (5 mg)SuppositoryRectalHoechst Roussel Canada Inc.1959-12-311999-08-11Canada
Proctosone OntDibucaine hydrochloride (.5 %) + Esculin (1 %) + Hydrocortisone acetate (.5 %) + Neomycin sulfate (1 %)OintmentRectalTechnilab Pharma Inc.1981-12-312004-08-03Canada
Categories
UNII
L6JW2TJG99
CAS number
85-79-0
Weight
Average: 343.4632
Monoisotopic: 343.225977187
Chemical Formula
C20H29N3O2
InChI Key
PUFQVTATUTYEAL-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
IUPAC Name
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
SMILES
CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC

Pharmacology

Indication

For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.

Structured Indications
Pharmacodynamics

Dibucaine is an amide-type local anesthetic, similar to lidocaine.

Mechanism of action

Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.

TargetActionsOrganism
ASodium channel protein type 5 subunit alpha
inhibitor
Human
ASodium channel protein type 10 subunit alpha
inhibitor
Human
UCalmodulin
inhibitor
Human
Absorption

In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Primarily hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Dibucaine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cinchocaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cinchocaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cinchocaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cinchocaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cinchocaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Azaperone.Vet Approved
AzelastineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cinchocaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cinchocaine.Approved, Investigational
BuprenorphineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cinchocaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cinchocaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cinchocaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cinchocaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cinchocaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cinchocaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorzoxazone.Approved
CitalopramThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cinchocaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cinchocaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cinchocaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cinchocaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cinchocaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cinchocaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cinchocaine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cinchocaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cinchocaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cinchocaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Cinchocaine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cinchocaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Cinchocaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cinchocaine.Approved
EthanolCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinchocaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinchocaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cinchocaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cinchocaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cinchocaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cinchocaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cinchocaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cinchocaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Cinchocaine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cinchocaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cinchocaine.Approved, Investigational
HydrocodoneCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cinchocaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cinchocaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cinchocaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cinchocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cinchocaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cinchocaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cinchocaine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cinchocaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cinchocaine.Approved
MethotrimeprazineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methylphenobarbital.Approved
MetyrosineCinchocaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cinchocaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Investigational
MirtazapineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cinchocaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cinchocaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cinchocaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Cinchocaine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cinchocaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Opium.Approved, Illicit
OrphenadrineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cinchocaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cinchocaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cinchocaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cinchocaine.Approved
ParaldehydeCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cinchocaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cinchocaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cinchocaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cinchocaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cinchocaine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Cinchocaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pomalidomide.Approved
PramipexoleCinchocaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cinchocaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinchocaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cinchocaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cinchocaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Cinchocaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Cinchocaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cinchocaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cinchocaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cinchocaine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cinchocaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Romifidine.Vet Approved
RopiniroleCinchocaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cinchocaine.Approved
RotigotineCinchocaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cinchocaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cinchocaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cinchocaine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cinchocaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cinchocaine.Approved
SultoprideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sultopride.Experimental
SuvorexantCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptCinchocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cinchocaine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrodotoxin.Investigational
ThalidomideCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cinchocaine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cinchocaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cinchocaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cinchocaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cinchocaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cinchocaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cinchocaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cinchocaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cinchocaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zolazepam.Vet Approved
ZolpidemCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Cinchocaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cinchocaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US1825623
General References
  1. Abdel-Ghani NT, Youssef AF, Awady MA: Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. Farmaco. 2005 May;60(5):419-24. [PubMed:15910814]
  2. Souto-Padron T, Lima AP, Ribeiro Rde O: Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. Parasitol Res. 2006 Sep;99(4):317-20. Epub 2006 Apr 13. [PubMed:16612626]
  3. Nounou MM, El-Khordagui LK, Khalafallah N: Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm. 2005 Sep-Oct;62(5):369-79. [PubMed:16459486]
External Links
Human Metabolome Database
HMDB14668
KEGG Drug
D00733
KEGG Compound
C07879
PubChem Compound
3025
PubChem Substance
46506734
ChemSpider
2917
BindingDB
48532
ChEBI
247956
ChEMBL
CHEMBL1086
Therapeutic Targets Database
DAP000507
PharmGKB
PA449286
Drugs.com
Drugs.com Drug Page
Wikipedia
Dibucaine
ATC Codes
S02DA04 — CinchocaineN01BB06 — CinchocaineS01HA06 — CinchocaineC05AD04 — CinchocaineD04AB02 — Cinchocaine
AHFS Codes
  • 84:08.00
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
OintmentTopical10 mg/g
CreamTopical10 mg/g
OintmentTopical.28 g/28g
OintmentTopical1 g/100g
OintmentRectal; Topical1 %
CreamTopical
OintmentRectal
SuppositoryRectal
Prices
Unit descriptionCostUnit
Dibucaine hcl powder4.74USD g
Nupercainal 1% ointment0.15USD g
Dibucaine 1% ointment0.12USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)99-101 °C (HCl salt)Not Available
water solubility42 mg/L (at 21 °C)BEILSTEIN
logP4.40HANSCH,C ET AL. (1995)
logS-3.7ADME Research, USCD
pKa8.85SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0389 mg/mLALOGPS
logP3.79ALOGPS
logP3.7ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)14.57ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.46 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity102.12 m3·mol-1ChemAxon
Polarizability40.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9876
Caco-2 permeable+0.5187
P-glycoprotein substrateSubstrate0.8702
P-glycoprotein inhibitor IInhibitor0.7536
P-glycoprotein inhibitor IINon-inhibitor0.8862
Renal organic cation transporterNon-inhibitor0.6349
CYP450 2C9 substrateNon-substrate0.8297
CYP450 2D6 substrateNon-substrate0.6415
CYP450 3A4 substrateSubstrate0.6842
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6424
Ames testAMES toxic0.6038
CarcinogenicityNon-carcinogens0.8128
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6763 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8924
hERG inhibition (predictor II)Inhibitor0.6851
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-000i-9000000000-11b0b035aed1c901a827
GC-MS Spectrum - CI-BGC-MSsplash10-0006-5009000000-4623c33d494376e699f3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0009000000-396529f9f1539ca4f5d2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0091000000-f6ba1af6a7e8fcdfaa16
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00xr-0190000000-9cd7408320081da0e435
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01b9-0960000000-48d5c97824dd28e11f73
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-cbd25496ff6fc8a2fa36
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-b4f898603ef48a2b9e29
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00xr-3980000000-e5e0b2d6136d950b770a

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinolones and derivatives. These are compounds containing a quinoline moiety which bears a ketone group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinolones and derivatives
Direct Parent
Quinolones and derivatives
Alternative Parents
Alkyl aryl ethers / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Quinolone / Alkyl aryl ether / Pyridine / Benzenoid / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine / Carboximidic acid / Carboximidic acid derivative / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, aromatic ether, monocarboxylic acid amide (CHEBI:247956)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Oka M, Itoh Y, Fujita T: Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. [PubMed:12354567]
  4. Louro SR, Anteneodo C, Wajnberg E: Carboxyl groups at the membrane interface as molecular targets for local anesthetics. Biophys Chem. 1998 Aug 4;74(1):35-43. [PubMed:9742684]
  5. Ryan SE, Demers CN, Chew JP, Baenziger JE: Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor. An infrared difference spectroscopy study. J Biol Chem. 1996 Oct 4;271(40):24590-7. [PubMed:8798723]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Louro SR, Anteneodo C, Wajnberg E: Carboxyl groups at the membrane interface as molecular targets for local anesthetics. Biophys Chem. 1998 Aug 4;74(1):35-43. [PubMed:9742684]
  4. Ryan SE, Demers CN, Chew JP, Baenziger JE: Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor. An infrared difference spectroscopy study. J Biol Chem. 1996 Oct 4;271(40):24590-7. [PubMed:8798723]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Muto Y, Kudo S, Nozawa Y: Effects of local anesthetics on calmodulin-dependent guanylate cyclase in the plasma membrane of Tetrahymena pyriformis. Biochem Pharmacol. 1983 Dec 1;32(23):3559-63. [PubMed:6140014]
  2. Volpi M, Sha'afi RI, Epstein PM, Andrenyak DM, Feinstein MB: Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin. Proc Natl Acad Sci U S A. 1981 Feb;78(2):795-9. [PubMed:6262771]
  3. Liu SH, Fu WM, Lin-Shiau SY: Studies on the inhibition by chlorpromazine of myotonia induced by ion channel modulators in mouse skeletal muscle. Eur J Pharmacol. 1993 Jan 26;231(1):23-30. [PubMed:7680317]
  4. Sambandam T, Gunasekaran M: Purification and properties of calmodulin from Phymatotrichum omnivorum. Microbios. 1993;73(294):61-74. [PubMed:8382768]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Elamin B: Dibucaine inhibition of serum cholinesterase. J Biochem Mol Biol. 2003 Mar 31;36(2):149-53. [PubMed:12689511]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:39